在研究结论与讨论部分，研究人员发现，通过 SNP 估计的 LDL-C 降低与 CAD 风险的显著降低密切相关。这意味着，LDL-C 降低药物靶点基因在降低 CAD 风险方面具有重要潜力，为未来临床治疗提供了新的方向。同时，研究还发现，不同基因对降低 CAD 风险的效果存在差异，LDLR 基因的影响最为显著。而且，亚洲人群与西方人群在 LDL-C 降低基因的 SNP 频率以及这些基因对 LDL-C ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...